Jan 10, 2018
My refuge again. #JTerm18 #HPTX (at Highland Park Library)
seen from Lithuania
seen from Morocco
seen from United States
seen from Japan
seen from United States
seen from United States
seen from China
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Indonesia
seen from Nepal
seen from Malaysia
seen from Germany
seen from United States
seen from United States
seen from United States
seen from United States
My refuge again. #JTerm18 #HPTX (at Highland Park Library)
New Post has been published on Stock Markets Daily
New Post has been published on http://www.stockmarketsdaily.com/downgrade-prospects-hyperion-therapeutics-inc-nasdaqhptx/12534/
Downgrade Prospects: Hyperion Therapeutics Inc (NASDAQ:HPTX)
(adsbygoogle = window.adsbygoogle || []).push();
Hyperion Therapeutics, Inc. (NASDAQ:HPTX) has been downgraded by 2 brokers in the last 2 days from buy to holds. With that in mind we have a look at what other brokers on the Street think of Hyperions prospects. [Trend Analysis]
Analysis
Hyperion Therapeutics, Inc. (NASDAQ:HPTX) last traded at $45.90 after moving down -0.17% for the trading day. The company last released their quarterly earnings results on Feb 26th for the period ended Dec-14. The company reported earnings of $0.37 against a Zack’s research estimate of -$0.13. This represents a 384.62% surprise on the expected result.
The current average broker recommendation for Hyperion Therapeutics, Inc., according to Zack’s research, is 1.67, based on 6 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see Hyperion Therapeutics, Inc. as a buy. The 12 month target consensus price estimate among these analysts for Hyperion Therapeutics, Inc. is currently at $43.00.
Out of the 6 broker recommendations for HPTX, 4 recommend it as a strong buy, 0 as a buy, 2 as a hold 0 as a sell and 0 as a strong sell.
For the current quarter, the consensus analyst estimate for Hyperion Therapeutics, Inc. (NASDAQ:HPTX) is $0.17, with analysts expecting year on year growth for the company of 37.50%
About Hyperion Therapeutics, Inc. (NASDAQ:HPTX)
Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company is developing Ravicti (TM) for urea cycle disorders and hepatic encephalopathy. Hyperion Therapeutics, Inc. is headquartered in South San Francisco, California.